As is different from the recommendations of the 2021 published ESC guidelines for the management of heart failure, only 1.9% of patients with compensated heart failure and 7.3% of acute decompensate HF patients received SGLT-2 inhibitors. This evidence concerns the gene SLC5A2 and heart failure.